Skip to main content
Clinical Trials/NCT01252901
NCT01252901CompletedNot Applicable

Registry for Patients With WT1 Mutation Associated Diseases

Universitätsklinikum Hamburg-Eppendorf1 site in 1 country52 target enrollmentStarted: October 2010Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
52
Locations
1

Study Overview

Brief Summary

The Wilms' tumor suppressor gene 1 (WT1) encodes for a transcription factor which plays an important role during urogenital development. Patients carrying a WT1 germline mutation show symptoms like proteinuria, Wilms tumors, genital malformations and kidney failure. Milder variants are possible and classification is not always possible. In this registry we are collecting detailed clinical data of affected individuals to establish genotype-phenotype correlations with the greater goal to optimize patient care.

Detailed Description

The Wilms' tumor suppressor gene 1 (WT1) encodes for a transcription factor which plays an important role during urogenital development. Patients carrying a WT1 germline mutation show symptoms like proteinuria, Wilms tumors, genital malformations and kidney failure, which usually occur in early childhood. Milder variants are possible and classification as one of the three rare syndromes associated with WT1 mutations (Denys-Drash syndrome, Frasier syndrome or WAGR syndrome) is not always possible. In this registry we are collecting detailed clinical data of affected individuals to establish genotype-phenotype correlations with the greater goal to optimize patient care.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Germline mutation in WT1 gene

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 1
Phase I pilot study of Wilms' tumor gene WT1 peptide pulsed dendritic cell vaccination combined with gemcitabine for patients with advanced pancreatic cancerunresectable pancreatic cancer
JPRN-UMIN000004855School of Medicine, Keio University10
Active, not recruiting
Not Applicable
Dendritic cell vaccine to treat cancer patientsTherapeutic vaccination with dendritic cells loaded with Wilms' tumor 1 protein in patients with solid tumorsMedDRA version: 14.0Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10046859Term: VaccinationSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2011-000547-24-BEAntwerp University Hospital
Active, not recruiting
Not Applicable
Therapeutic efficacy of Wilms tumor gene (WT1) mRNA-electroporated autologous dendritic cell vaccination in patients with myeloid malignancies and multiple myeloma:a phase II trial.Therapeutic vaccination with dendritic cells loaded with wilms' tumor 1 protein in patients with myeloid malignancies and multiple myelomaMedDRA version: 12.0Level: LLTClassification code 10046859Term: VaccinationMedDRA version: 12.0Level: LLTClassification code 10024329Term: LeukemiaMedDRA version: 12.0Level: LLTClassification code 10028228Term: Multiple myeloma
EUCTR2009-015720-28-BEAntwerp University Hospital
Not yet recruiting
Phase 1
Phase I study of Wilms' tumor gene WT1 peptide vaccination combined with gemcitabine for patients with advanced non-small-cell lung canceradvanced or recurrent non-small-cell lung cancer
JPRN-UMIN000005226School of Medicine, Keio University10
Completed
Phase 1
Phase I study of Wilms' tumor gene WT1 peptide pulsed dendritic cell vaccination combined with docetaxel for patients with advanced or recurrent esophageal cancerAdvanced or recurrent esophageal cancer
JPRN-UMIN000006704School of Medicine, Keio University10
Registry for Patients With Wilms' Tumor... | Clinical Trial